| Balance Sheets | 2025-09-30 | |||
|---|---|---|---|---|
| Cash | 10,375 | |||
| Prepaid expenses and other current assets | 653 | |||
| Total current assets | 11,028 | |||
| Machinery and equipment, net | 849 | |||
| Operating lease right-of-use assets, net | 2,012 | |||
| Other noncurrent assets | 140 | |||
| Total assets | 14,029 | |||
| Accounts payable-Nonrelated Party | 1,143 | |||
| Accounts payable-Related Party | 5 | |||
| Accrued expenses and other current liabilities-Nonrelated Party | 1,396 | |||
| Accrued expenses and other current liabilities-Related Party | 778 | |||
| Term notes payable, net of discount, including accrued interest-Related Party | 405 | |||
| Finance lease liability, current | 112 | |||
| Operating lease right-of-use liability, current | 1,354 | |||
| Total current liabilities | 5,193 | |||
| Operating lease right-of-use liability, noncurrent | 640 | |||
| Finance lease liability, noncurrent | 197 | |||
| Promissory note | 600 | |||
| Warrant liability | 186 | |||
| Related party warrant liability | 15 | |||
| Total liabilities | 6,831 | |||
| Common stock, 0.0001 par value, 330,000 shares authorized 6,906 and 1,730 shares issued and outstanding as of september 30, 2025, and december 31, 2024, respectively | 1 | |||
| Additional paid-in capital | 144,495 | |||
| Accumulated other comprehensive income loss, net of tax | -13 | |||
| Accumulated deficit | -137,565 | |||
| Total stockholders equity | 6,918 | |||
| Noncontrolling interest | 280 | |||
| Total equity | 7,198 | |||
| Total liabilities and total equity | 14,029 | |||
Calidi Biotherapeutics, Inc. (CLDI)
Calidi Biotherapeutics, Inc. (CLDI)